Loading…
Soligenix, Inc. is projected to rise to $1.10 by 2027, a +27% move from its current price of $0.8657. SNGX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.7745 | $0.8668 | $0.9702 | +0.13% |
| May 30 | $0.7401 | $0.8679 | $1.02 | +0.26% |
| May 31 | $0.715 | $0.869 | $1.06 | +0.38% |
| Jun 1 | $0.6946 | $0.8701 | $1.09 | +0.51% |
| Jun 2 | $0.6773 | $0.8712 | $1.12 | +0.64% |
| Jun 3 | $0.662 | $0.8724 | $1.15 | +0.77% |
| Jun 4 | $0.6484 | $0.8735 | $1.18 | +0.90% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.6484 | $0.8735 | $1.18 | +0.90% |
| Week 2 | $0.5782 | $0.8813 | $1.34 | +1.80% |
| Week 3 | $0.5307 | $0.8892 | $1.49 | +2.72% |
| Week 4 | $0.4943 | $0.8972 | $1.63 | +3.64% |
| Week 5 | $0.4649 | $0.9052 | $1.76 | +4.57% |
| Week 6 | $0.4402 | $0.9134 | $1.90 | +5.51% |
| Week 7 | $0.4189 | $0.9216 | $2.03 | +6.45% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Soligenix, Inc. is a late-stage biopharmaceutical company focusing on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions.
The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology in Phase 2a to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology in Phase 2a for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies; ThermoVax for thermostabilizing vaccines; CiVax for COVID-19 prevention; and vaccine programs targeting filoviruses such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc.
and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Soligenix, Inc. (SNGX) is currently trading at $0.8657 with a market capitalization of $12.83M and a rank of 5029. The price outlook provided shows a path of growth across multiple years, with the 2026 average price projected at $0.8657 and a longer-term bullish trajectory evident in the year-by-year forecast, including higher averages and expanding price ranges through 2050.
The 30-day technical picture presents a context for near-term price action and supports a longer-term bull case.
A major floor 67.7% below — a decisive break under it would weaken the trend.
The nearest floor, 67.7% below — buyers have tended to step in here.
The nearest ceiling, 64.0% above — a clean break opens room to run.
A major ceiling 130.6% above — clearing it would confirm fresh momentum.
Key SNGX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SNGX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.51 | Buy | $0.575 | Buy |
| MA 10 | $0.447 | Buy | $0.4988 | Buy |
| MA 20 | $0.385 | Buy | $0.5349 | Buy |
| MA 50 | $0.8664 | Sell | $0.7633 | Buy |
| MA 100 | $1.05 | Sell | $1.00 | Sell |
| MA 200 | $1.49 | Sell | $1.43 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 64.88 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 479.01 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.07 | Buy |
| ROC (12) | 200.00 | Buy |
| Bollinger %B (20,2) | 1.49 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -3.26 | Sell |
| Awesome (5,34) | -0.21 | Sell |
| Ultimate (7,14,28) | 84.26 | Sell |
| Momentum (10) | 0.56 | Buy |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 0.58 | Buy |
| ADX (14) | 37.24 | Buy |
| ATR (14) | 0.07 | Info |
The near-term technical picture is neutral, with RSI14 at 60. The 50-day simple moving average sits at $0.8664, while the 200-day simple moving average stands at $1.49, suggesting limited near-term momentum relative to longer-term levels.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.28 | $0.8657 | $1.07 | 0% | Neutral | |
| $0.7912 | $1.10 | $1.65 | +27% | Bullish | |
| $0.9131 | $1.35 | $2.15 | +56% | Bullish | |
| $0.9321 | $1.45 | $2.43 | +67% | Bullish | |
| $0.8489 | $1.38 | $2.41 | +60% | Bullish | |
| $0.7426 | $1.26 | $2.28 | +46% | Bullish | |
| $0.7427 | $1.32 | $2.45 | +52% | Bullish | |
| $0.7605 | $1.40 | $2.68 | +62% | Bullish | |
| $0.9713 | $1.86 | $3.65 | +115% | Bullish | |
| $1.05 | $2.10 | $4.21 | +143% | Bullish | |
| $1.30 | $2.89 | $6.36 | +234% | Bullish | |
| $1.53 | $3.41 | $7.84 | +294% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.28 | $0.8657 | $1.04 | +0.00% |
| June 2026 | $0.8013 | $0.961 | $1.19 | +11.00% |
| July 2026 | $0.7974 | $0.9726 | $1.24 | +1.21% |
| August 2026 | $0.7298 | $0.902 | $1.17 | -7.25% |
| September 2026 | $0.7199 | $0.8997 | $1.19 | -0.25% |
| October 2026 | $0.7259 | $0.9164 | $1.23 | +1.86% |
| November 2026 | $0.659 | $0.8395 | $1.14 | -8.39% |
| December 2026 | $0.6055 | $0.7782 | $1.07 | -7.30% |
Click any year to see its month-by-month SNGX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect SNGX to range from $0.28 to $1.07 through 2026. The $0.8657 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The SNGX price prediction for 2027 points to an average of $1.10 (low $0.7912, high $1.65) — a potential gain of +27% on today's $0.8657. Momentum favours further upside here.
In 2028, SNGX is projected to trade between $0.9131 and $2.15, averaging $1.35 — a potential gain of +56% from today's $0.8657. That is up +22% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Soligenix, Inc.'s 2029 outlook centres on $1.45, within a $0.9321 to $2.43 range. That is up +7% on the projected 2028 average. That marks a +67% change versus current levels. Momentum favours further upside here.
By 2030, SNGX could reach as high as $2.41, with a base case around $1.38 and support toward $0.8489 — roughly +60% from $0.8657. Buyers look set to stay in control over this stretch.
Expect SNGX to range from $0.7426 to $2.28 through 2031. The $1.26 average target implies a +46% move from current prices. That is -9% versus the projected 2030 average. Momentum favours further upside here.
The SNGX price prediction for 2032 points to an average of $1.32 (low $0.7427, high $2.45) — a potential gain of +52% on today's $0.8657. Buyers look set to stay in control over this stretch.
In 2033, SNGX is projected to trade between $0.7605 and $2.68, averaging $1.40 — a potential gain of +62% from today's $0.8657. That is up +7% on the projected 2032 average. Momentum favours further upside here.
Soligenix, Inc.'s 2034 outlook centres on $1.86, within a $0.9713 to $3.65 range. That is up +33% on the projected 2033 average. That marks a +115% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, SNGX could reach as high as $4.21, with a base case around $2.10 and support toward $1.05 — roughly +143% from $0.8657. Momentum favours further upside here.
Expect SNGX to range from $1.30 to $6.36 through 2040. The $2.89 average target implies a +234% move from current prices. That is up +37% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The SNGX price prediction for 2050 points to an average of $3.41 (low $1.53, high $7.84) — a potential gain of +294% on today's $0.8657. Momentum favours further upside here.
Investing $1,000 in SNGX today (≈ 1,155.134573 SNGX) could be worth
$3,935.25
+$2,935.25 (+294%) by 2050 · US Dollar
Based on the average projected SNGX price of $3.41 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SNGXwould be worth at today's price.
$1,000 invested in SNGX on May 27, 2025 (≈ 523.560219 SNGX) would be worth
$453.25
-$546.75 (-54.7%) today · 0.45× · US Dollar
Based on a SNGX entry price of $1.91 vs. today's $0.8657.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.39 | $2,219.74 | +122.0% |
| 1 month ago | $1.42 | $609.65 | -39.0% |
| 3 months ago | $1.15 | $752.78 | -24.7% |
| 6 months ago | $1.59 | $544.47 | -45.6% |
| 1 year ago | $1.91 | $453.25 | -54.7% |
| All time (5.0y) ago | $252 | $3.44 | -99.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SNGX forecast.
Our base-case forecast reaches $1.70 around 2034.
Implied market cap at $1.70: $25.2M
The multi-year forecast shows a bullish trajectory from 2027 onward, with the average price rising from $1.10 in 2027 to $3.41 in 2050 and a progressive series of higher highs implied by the max forecasts. Notable year-by-year highlights include 2027 avg $1.10, 2028 avg $1.35, 2029 avg $1.45, 2030 avg $1.38, 2034 avg $1.86 and max $3.65, 2035 avg $2.10 and max $4.21, 2040 avg $2.89 and max $6.36, and 2050 avg $3.41 with max $7.84. The forecast also shows robust ROIs in several years, such as 27 in 2027, 55.5 in 2028, 67.1 in 2029, 59.5 in 2030, 115.4 in 2034, 143.1 in 2035, 233.8 in 2040, and 293.5 in 2050.
Overall, the outlook is bullish for the long term, though these are estimates and not guarantees, and carries inherent uncertainty and risk.
Tap a question to reveal the answer.
The forecast shows avg $1.10 with min $0.7912 and max $1.65; ROI 27; sentiment BULLISH.
The forecast is broadly bullish across multiple future years, with rising averages and ROIs (e.g., 2028 ROI 55.5, 2029 ROI 67.1, 2034 ROI 115.4, 2050 ROI 293.5). The current price is $0.8657 and market cap is $12.83M, but these are estimates and not guarantees.
Yes. In 2031 the max forecast is $2.28 and the avg is $1.26, with a min of $0.7426 and ROI 45.8; sentiment is bullish.
The 2050 forecast max is $7.84, with an average of $3.41 and a min of $1.53; ROI 293.5 and sentiment bullish.
Current price is $0.8657. The 30-day range is from $0.412 to $1.82, with a support at $0.28 and resistance at $1.42.
Soligenix, Inc. Community Discussion
0Share your Soligenix, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.